Investigators sought to evaluate changes in the estimated CV risk of men with prostate cancer after 6 months of hormone therapy using clinical tools established for the general population. A post-hoc ...

—As more men are cured of prostate cancer, or are long-term survivors, the challenges of survivorship are in the spotlight. Improved screening practices, earlier detection, and better therapies have ...

A predictive artificial intelligence (AI) biomarker of androgen deprivation therapy (ADT) benefit in prostate cancer was validated in a recent study published in NEJM Evidence. Results of a phase 3 ...

Metformin did not prevent development of metabolic syndrome in men receiving androgen deprivation therapy for prostate cancer in a phase III trial. Metformin was associated with improvement in weight, ...

The presence of certain comorbidities prior to androgen deprivation therapy (ADT) for prostate cancer may be associated with a greater risk of cardiovascular events after starting ADT, recent research ...

The phase 3 ARASTEP trial will investigate Nubeqa plus androgen-deprivation therapy in certain patients with hormone-sensitive prostate cancer. Researchers are looking to enroll approximately 750 ...

April 30, 2009 — Androgen-deprivation therapy (ADT) is a common treatment for men with prostate cancer, but patients who do undergo this therapy are at an increased risk for skeletal fracture, ...

Data from a new study published in NEJM Evidence shows promise for personalized use of short term ADT in men with predominantly intermediate-risk prostate cancer. The study involved ArteraAI, a ...

Medically reviewed by Matthew Wosnitzer, MD Key Takeaways Most prostate cancers become castration-resistant in about two to ...

JCO Precision Oncology Conversations features discussions with leading authors of JCO Precision Oncology articles, hosted by Dr. Abdul Rafeh Naqash. Join our experts in engaging conversations as they ...